PE20110583A1 - Comprimidos de capecitabina de disgregacion rapida - Google Patents

Comprimidos de capecitabina de disgregacion rapida

Info

Publication number
PE20110583A1
PE20110583A1 PE2011001070A PE2011001070A PE20110583A1 PE 20110583 A1 PE20110583 A1 PE 20110583A1 PE 2011001070 A PE2011001070 A PE 2011001070A PE 2011001070 A PE2011001070 A PE 2011001070A PE 20110583 A1 PE20110583 A1 PE 20110583A1
Authority
PE
Peru
Prior art keywords
capecitabin
composition
disgregation
tablets
rapid
Prior art date
Application number
PE2011001070A
Other languages
English (en)
Inventor
Maria Oksana Bachynsky
Mohammad Rashed
Navnit Hargovindas Shah
Paul Anthony Samtak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600677&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20110583A1 publication Critical patent/PE20110583A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA RECUBIERTA POR UNA PELICULA, DONDE DICHA COMPOSICION COMPRENDE: a) CAPECITABINA (5'-DESOXI-5-FLUORO-N-[(PENTILOXI)-CARBONIL]-CITIDINA) EN UNA CANTIDAD DE ENTRE 10% A 50% DEL PESO TOTAL DE LA COMPOSICION DEL NUCLEO, b) UNA FORMULACION DISGREGANTE QUE CONSITE EN MANITOL (90%), CROSPOVIDONA (5%) Y ACETATO DE POLIVINILO (5%). TAMBIEN PUEDE EMPLEARSE OTROS DISGREGANTES TALES COMO CROSPOVIDONA DE TAMANO DE PARTICULA INFERIOR A 15 MICRAS, CROSCARMELOSA SODICA, GLICOLATO DE ALMIDON SODICO E HIDROXIPROPILCELULOSA, O UNA COMBINACION DE LAS MISMAS. DICHA COMPOSICION SE PRESENTA BAJO LA FORMA DE UN COMPRIMIDO QUE SE DISGREGA RAPIDAMENTE
PE2011001070A 2008-12-16 2009-12-07 Comprimidos de capecitabina de disgregacion rapida PE20110583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12276608P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
PE20110583A1 true PE20110583A1 (es) 2011-08-17

Family

ID=41600677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001070A PE20110583A1 (es) 2008-12-16 2009-12-07 Comprimidos de capecitabina de disgregacion rapida

Country Status (17)

Country Link
US (1) US20110027374A1 (es)
EP (1) EP2379065A2 (es)
JP (1) JP2012512142A (es)
KR (1) KR20110086857A (es)
CN (1) CN102369002A (es)
AR (1) AR074739A1 (es)
AU (1) AU2009328348A1 (es)
BR (1) BRPI0922983A2 (es)
CA (1) CA2745279A1 (es)
IL (1) IL212735A0 (es)
MX (1) MX2011006026A (es)
PE (1) PE20110583A1 (es)
RU (1) RU2011129205A (es)
SG (1) SG172191A1 (es)
TW (1) TW201028156A (es)
WO (1) WO2010069795A2 (es)
ZA (1) ZA201103986B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107252419A (zh) 2010-12-22 2017-10-17 巴斯夫欧洲公司 快速崩解的固体包衣剂型
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
EP2747571A4 (en) * 2011-08-24 2015-05-27 David Kerr COMBINED COMBINED CHEMOTHERAPY
CN102988320B (zh) * 2012-12-13 2014-04-16 哈药集团技术中心 一种卡培他滨分散片及其制备方法
CN104337783B (zh) * 2013-08-02 2018-06-22 山东新时代药业有限公司 一种卡培他滨片剂及其制备方法
CN104997744B (zh) * 2015-08-04 2018-01-23 青岛市中心医院 一种高稳定性卡培他滨片剂及其制备方法
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
JP6866113B2 (ja) * 2016-11-01 2021-04-28 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤
JP6792418B2 (ja) * 2016-11-08 2020-11-25 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤の製造方法
KR20200097702A (ko) * 2017-12-08 2020-08-19 에프. 호프만-라 로슈 아게 약학 제형
WO2021033144A1 (en) * 2019-08-20 2021-02-25 Intas Pharmaceuticals Ltd. Oral suspension of capecitabine
MX2022014094A (es) * 2020-05-19 2022-12-08 Cellix Bio Private Ltd Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US20040071772A1 (en) * 2001-03-06 2004-04-15 Shoichi Narita Preparations quickly disintegrating in oral cavity
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE602004004782T2 (de) * 2004-09-09 2007-10-31 Laboratorio Medinfar-Produtos Farmacéuticos, S. A. Schnell wasserdispergierbare und Domperidon enthaltende Tabletten
EP1839650A1 (en) * 2004-12-28 2007-10-03 Eisai R&D Management Co., Ltd. Quick disintegration tablet and method of producing the same
DE112006000873T5 (de) * 2005-04-12 2008-03-06 Elan Pharma International Ltd. Zusammensetzungen mit modifizierter Freisetzung, umfassend ein Fluorcytidin-Derivate zur Behandlung von Krebs
EP1965761B1 (de) * 2005-12-21 2015-07-01 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
CN101583379B (zh) * 2006-10-05 2013-04-03 约翰斯霍普金斯大学 使用优良聚合物纳米粒子的水溶性差药物的水可分散性口服，肠胃外和局部制剂
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets

Also Published As

Publication number Publication date
ZA201103986B (en) 2012-02-29
US20110027374A1 (en) 2011-02-03
MX2011006026A (es) 2011-06-21
WO2010069795A2 (en) 2010-06-24
BRPI0922983A2 (pt) 2016-01-26
CA2745279A1 (en) 2010-06-24
AU2009328348A1 (en) 2010-06-24
JP2012512142A (ja) 2012-05-31
WO2010069795A3 (en) 2010-10-07
AR074739A1 (es) 2011-02-09
SG172191A1 (en) 2011-07-28
TW201028156A (en) 2010-08-01
KR20110086857A (ko) 2011-08-01
IL212735A0 (en) 2011-07-31
RU2011129205A (ru) 2013-01-27
CN102369002A (zh) 2012-03-07
EP2379065A2 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
PE20110583A1 (es) Comprimidos de capecitabina de disgregacion rapida
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
AR067077A1 (es) Preparado solido farmaceutico y metodo de produccion del mismo
HRP20110094T1 (hr) Čvrsti pripravak koji sadrži alogliptin i pioglitazon
CO6280463A2 (es) Formulaciones farmaceuticas solidas que comprenden bibw 2992
ECSP14013168A (es) Tableta a prueba de manipulación que proporciona liberación de fármaco inmediato
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
PE20130378A1 (es) Formulaciones de apixaban
BR112014018378A8 (pt) Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
MX2015012092A (es) Capsulas y comprimidos solidos de benzonatato de liberacion modificada.
CR10668A (es) Comprimidos pediatricos de capecitabina
CO6220900A2 (es) Forma dosificadora novedosa
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
PE20150607A1 (es) Composicion farmaceutica que comprende fimasartan e hidroclorotiazida
CL2014000623A1 (es) Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades.
RU2019138248A (ru) Фармацевтическая композиция для перорального введения, содержащая энзалутамид
PE20061058A1 (es) Composicion farmaceutica que comprende ixabepilona y proceso de preparacion
JP2015129124A5 (es)
PE20140962A1 (es) Una formulacion farmaceutica solida
GT201400094A (es) Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
JP2015534970A5 (es)
PE20110925A1 (es) Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida

Legal Events

Date Code Title Description
FC Refusal